The present invention relates generally to a modular biopsy, ablation and delivery needle apparatus that allows a biopsy needle to be inserted into a delivery needle, and, absent the biopsy needle, allows an inner ablation needle to be introduced and engaged with the delivery needle to form a microwave antenna. The present invention also relates to methods for biopsying and ablating tumors and coagulating the insertion track using the modular apparatus.
In the U.S., the lifetime chance of developing an invasive cancer is 46% for men and 38% for women. Cancer is the second leading cause of death in the U.S. and is a major cause of death worldwide. In the U.S. in 1998, there were an estimated 564,800 deaths due to cancer with 1,228,600 new cases of invasive cancer diagnosed. Over 40% of the deaths are associated with primary and metastatic liver cancer.
Outside the U.S., primary liver cancer (hepatocellular carcinoma) accounts for one of the largest cancer-related mortalities in the world (about 1,250,000 per year) in adults. In Japan, liver cancer is the third most common cause of death in men.
Of the over 1 million newly diagnosed U.S. cancer patients each year, hundreds of thousands will develop liver cancer during the course of the disease. For liver metastases that result in or are associated with death, estimates vary but are conservatively estimated at more than 230,000 annually in the U.S. Numerous studies of colorectal carcinoma have shown that liver metastasis is the primary determinant of patient survival.
Patterns of metastasis can be explained in part by the architecture of the circulatory system. Cancers in the intestine and many other tissues often colonize the liver first because the liver contains the first downstream capillary bed. It is estimated that 131,600 new cases of colorectal cancer were detected in 1998 and that 98,000 of them will eventually have liver involvement. Due to a lack of treatment options and the likelihood of recurrence, the American Joint Committee on Cancer projects that less than 1% of the patients diagnosed with nonresectable liver metastasis will be alive in 5 years.
Unfortunately, except for the small number of patients who have a form of cancer that can be surgically resected, there is no effective treatment. Therapies for nonresectable tumors include chemotherapy, radiation, transcatheter arterial embolization, chemoembolization and cryotherapy. Of particular interest are the percutaneous ablative techniques using ethanol, acetic acid, hot saline solution, laser, radlofrequency (RF), microwave, gene therapy and focused ultrasound.
Recent improvements in computed tomography (CT), ultrasound imaging and magnetic resonance imaging (MRI) have enabled physicians to detect tumors at an earlier stage and to locate them more precisely. These improvements have increased the use of laparoscopic and percutaneous procedures. As a result, RF, microwave, and cyroprobe devices have been developed to be used in the treatment of preselected sites. A number of problems exist with respect to these currently available devices. For example, cyroprobes generally require laparotomy because of their relatively large diameter, precluding a simpler, less traumatic approach. RF ablation relies on electrical conduction to deliver energy to tissues away from an RF ablation electrode. As tissue adjacent to the RF ablation electrode becomes desiccated or charred, the impedance increases, thereby limiting conduction through the desiccated or char-red tissue. In addition, scar tissue, blood vessels or other tissue inhomogeneity within the ablation site may alter the conduction path of the RF current. Microwave coagulation therapy (MCT), however, destroys the diseased tissue though propagation of electromagnetic waves from a microwave antenna. Because the energy is deposited into the tissue away from the antenna without relying solely on conduction currents, little or no charring occurs with microwave coagulation therapy as compared to RF ablation methods. Furthermore, any charring that might occur does not affect energy deposition patterns to the extent that it would for RF ablation methods because energy can be propagated beyond any charred tissue since conduction through the charred tissue is not required. Therefore, microwave antennas can ablate tissue with little or no charring and with little or no alteration of their energy deposition patterns (typically measured by a specific absorption rate (SAR)) by tissue inhomogeneities. Despite the advantages offered by MCT, a need in the art exists for small-diameter microwave. antennas that can precisely follow the biopsy needle track.
This need in the art is particularly acute in liver surgery. For instance, excessive bleeding and bile leakage during surgical procedures within the liver are common. Not surprisingly, large instruments are more traumatic than smaller ones. Furthermore, attempts at biopsy and thermotherapy of tumors can result in seeding of the carcinoma along the track during instrument removal and additional bleeding along the track. Localizing the tumor site can also be a problem and can result in additional trauma and bleeding, for instance, when a biopsy tool is used to sample and localize the tumor and subsequently the thermotherapy device is reinserted to treat the tumor.
Accordingly, there is a need for a small diameter delivery device that can facilitate the biopsy and ablation of a tumor through a single protected puncture site without the need to withdraw the device from the puncture site during biopsying and ablation. Further, there is a need for a device that can efficiently ablate the track during removal to reduce bleeding and the chances of track seeding.
The present invention is directed to a modular biopsy and microwave ablation needle and delivery apparatus adapted for in situ assembly, biopsy and ablation of tumors in tissues, and ablation of the track upon removal of the apparatus. More particularly the apparatus is adapted to the biopsy and ablation of tumors in solid organs that have a propensity to bleed, for instance, the liver. The present invention also relates to methods for the biopsy and ablation of tumors using the modular biopsy and microwave ablation needle and delivery apparatus.
Generally, a modular needle apparatus for performing biopsy and ablation of tissue abnormalities through a puncture site comprises an elongated hollow delivery needle, a biopsy needle, and an ablation needle. The hollow delivery needle extends longitudinally a first predetermined distance from an open proximal end to an open distal end, with a lumen extending therebetween. The lumen may accommodate either the biopsy needle or the ablation needle inserted through the open proximal end. The distal end of the delivery needle may be sharpened to pierce tissue. Alternatively or additionally, an obturator may be inserted within the lumen of the delivery needle to stiffen the delivery needle and provide a sharp tip to facilitate piercing tissue. As yet another alternative, the biopsy needle acts as the obturator of the delivery needle, and the biopsy needle and delivery needle are inserted into tissue as a unit. In that case, the biopsy needle itself serves to stiffen the assembly and provide a sharp point for piercing tissue. The biopsy needle may be of any type known in the art and may comprise a single piece, two pieces, or more.
Both the biopsy needle and the ablation needle are longer than the first predetermined distance such that when either the biopsy needle or the ablation needle is inserted into the proximal port and distally displaced within the lumen of the delivery needle, a distal projection of either the biopsy needle or the ablation needle may extend beyond the distal end of the delivery needle. The distal projection of the ablation needle is adapted to form a microwave antenna. The microwave antenna may comprise one of many forms known in the art, for example, a monopole, a dipole or a helical coil antenna.
In a preferred embodiment, the delivery needle has a first connector adapted to connect to a second connector of the ablation needle when the ablation needle is inserted within the lumen of delivery needle. The ablation needle comprises a center conductor at least partially surrounded by a dielectric material, and the delivery needle comprises a conducting material wherein the combination of the delivery needle, the dielectric material and the center conductor comprise a coaxial transmission line when the first and second connectors are connected. The delivery needle thus comprises the outer conductor of the coaxial transmission line and the inner conductor of the ablation needle comprises the inner conductor of the coaxial transmission line. The ablation needle extends longitudinally a second predetermined distance from the second connector wherein the second predetermined distance is greater than the first predetermined distance whereby the ablation needle forms the distal projection extending beyond the distal end of the delivery needle when the first and second connectors are connected. The distal projection of the ablation needle forms the microwave antenna that is coupled to the coaxial transmission line.
In another embodiment of the invention, the delivery needle and the ablation needle are not adapted to form a transmission line. Instead, the transmission line is contained within the ablation needle. The delivery needle extends longitudinally a first predetermined distance from an open proximal end to an open distal end, with a lumen extending therebetween as described generally above. The ablation needle extends longitudinally a third predetermined distance from a distal end wherein the third predetermined distance is greater than the first predetermined distance whereby the ablation needle forms a distal projection extending beyond the distal end of the delivery needle when the ablation needle is distally displaced within the lumen of the delivery needle. The distal projection of the ablation needle forms the microwave antenna. The remainder of the ablation needle comprises a transmission line that couples to the microwave antenna. The microwave antenna may be a dipole, a monopole or a helical coil antenna.
For the embodiments described herein, the biopsy needle, which may be an aspirating or a coring type, extends distally from its proximal end a fourth predetermined distance wherein the fourth predetermined distance is greater than the first predetermined distance. The biopsy needle may comprise a cannula and a stylet adapted to be disposed within the cannula. The stylet may include a matched point wherein the matched point matches a distal end of the cannula.
Methods of ablating tissue are also described. First, an ablation system as described herein is provided. Then, the distal end of the delivery needle is introduced into a tissue sample in a predetermined area. Next, the distal end of the ablating needle is inserted into the lumen of the delivery needle through the open proximal end, and the ablating needle is then advanced until the first and second connectors are adjacent one another. Next, the first and second connectors are connected. Then, a coaxial connector of the modular needle apparatus is electrically coupled to a coaxial connector of the microwave energy source. Microwave energy may then be delivered to the microwave antenna, thus ablating the tissue abnormality in the predetermined area. In other embodiments, the steps of inserting a biopsy needle into the delivery needle, biopsying the tissue and removing the biopsy needle with a tissue sample precede or follow the step of inserting the ablation needle.
Withdrawing the ablation needle from the tissue sample after the ablation of the tissue abnormality has been performed leaves an insertion track. The ablation needle may “seed” diseased cells within the insertion track as the ablation needle is withdrawn. The present invention is directed towards devices and methods to ablate the insertion track, thereby killing any diseased cells within the insertion track. In addition, track ablation minimizes bleeding, and, if performed within the liver, stems bile leakage. To minimize the damage to healthy tissue, the insertion track should be ablated with minimal overlap between adjacent ablations. Thus, the modular needle apparatus preferably has a plurality of first markings on its surface wherein the plurality of first markings are spaced apart a distance approximately equal to an effective antenna length of the microwave antenna. After ablating the tissue abnormality, a clinician may partially withdraw the ablation needle from the insertion track approximately an effective antenna length as gauged by observing the plurality of first markings. The clinician may then perform an ablation of the insertion track. The steps of partially withdrawing and ablating the insertion track may be repeated as required to complete the track ablation. To aid the determination of whether the track ablation has been completed, the modular needle apparatus preferably further comprises a second marking adjacent a proximal edge of an antenna radiation pattern of the microwave antenna. In such an embodiment, the steps of partially withdrawing the modular needle apparatus and ablating the insertion track are repeated until a partial withdrawing of the modular needle apparatus positions the second marking adjacent an edge of an organ containing the tissue abnormality. At this point, the partial withdrawing step is stopped and a final ablation of the insertion track performed. Note that although the plurality of first markings and the second markings are described with respect to the delivery needle of the present invention, these markings may be applied to any suitable interstitial ablation device.
Because only a small area surrounding the insertion track need be ablated to prevent seeding, bleeding and (if applicable) bile leakage, the clinician may decrease the diameter of the field of the antenna and/or lengthen the field to speed track ablation time. Such changes in the field will also minimize damage to healthy tissue surrounding the insertion track.
It is to be noted that the plurality of first markings and the second marking and methods of using the same may be applied to other interstitial thermotherapy devices such as RF ablation devices or cryoprobes. In these embodiments, the plurality of first markings would be spaced apart an “effective ablation” length which is defined analogously to the effective antenna length. The effective ablation length thus represents the extent of effectively ablated tissue after performing an ablation with the interstitial thermotherapy device.
Additional objects and features of the present invention will become apparent from consideration of the following description taken in conjunction with the accompanying drawings.
a is a side view of a hollow delivery needle wherein the first connector comprises an outer portion of a coaxial connector according to one embodiment of the invention.
b is an isometric view of the proximal end of the hollow delivery needle of
c is a side view of an ablation needle wherein the second connector comprises an inner portion of a coaxial connector according to one embodiment of the invention.
d is a side view of a modular needle apparatus wherein the ablation needle of
e is a side view of the delivery needle wherein a distal portion is narrower in diameter than the remainder of the delivery needle.
f is a side view of an ablation needle further comprising a proximal coaxial extension wherein the second connector comprises a threaded portion at the distal end of an outer conductor of the proximal coaxial extension.
g is a side view of a delivery needle wherein the first connector comprises a threaded portion at its proximal end.
a is a side view of an open-tip monopole antenna according to one embodiment of the invention.
b is a side view of a dielectric or metal tip monopole antenna according to one embodiment of the invention.
c is a side view of a dipole antenna according to one embodiment of the invention.
d is a side view of a dipole antenna according to one embodiment of the invention.
e is a side view of a helical coil antenna according to one embodiment of the invention.
Turning now to
In an alternate embodiment, illustrated in
It is to be noted that by coupling the delivery needle 10 with the ablation needle 35 to create the coaxial transmission line 50 feeding the microwave antenna 40, the largest diameter that must enter the tissue may be kept very small, preferably of 17 gauge or higher, and more preferably 18 gauge or higher. As used herein, “gauge” shall refer to the outer diameter of a needle unless otherwise indicated. For such embodiments, the ablation needle 35 comprises a center conductor 55 circumferentially surrounded by a dielectric material 60. The dielectric material 60 may comprise a ceramic material, a fluoropolymer such as polytetrafluoroethylene (PTFE) or expanded PTFE, polyethylene (PE), silicone or other suitable materials. The dielectric material 60 is sized to fill the lumen 20 of the delivery needle 35. The diameter of the center conductor 55 and the inner diameter of the outer conductor 16 are chosen according to the equation:
Z=(138/(∈)1/2))log10(D/d)
where Z is the characteristic impedance, ∈ is the dielectric constant of the dielectric material 60, D is the inner diameter of outer conductor 16, and d is the diameter of center conductor 55. Typically, Z is chosen to be 50Ω. The value of ∈ is typically between 1 and 10, for example, the ∈ of PTFE is 2.1.
In addition, to promote efficient conduction along the coaxial transmission line 50, the inner surface of outer conductor 16 of the delivery needle 10 may be coated with a layer of very conductive metal such as Ag, Au, Cu or Al preferably to a thickness of at least the skin depth, or depth of penetration, δ. The skin depth in meters is given by the following equation:
δ=Sqrt (2/(ωμσ))
where ω=2π frequency (in Hz), μ is the permeability (or rate of absorption) of the very conductive metal in henrys/meter, and σ is the conductance in mhos/meter. Similarly, the base metal forming the center conductor 55 in the ablation needle 35 may be coated with a layer of a very conductive metal preferably to a thickness of at least the skin depth.
To complete the coaxial transmission line 50, the ablation needle 35 and the delivery needle 10 are coupled together using a first connector 70 on the delivery needle 10 and a second connector 65 on the ablation needle 35. The first and second connectors 70 and 65 may be implemented in many different ways. For example, in a preferred embodiment, illustrated in
Those of ordinary skill in the art will appreciate the numerous ways in. which connectors 65 and 70 may engage one another to form coaxial connector 75. For example, rather than using threads 37 and 38, a latching mechanism using biased tabs engaging matching grooves may be employed. Regardless of the manner in which connectors 65 and 70 connect together, the result is that the inner contact 69 of the coaxial connector 75 electrically couples to the center conductor 55 of the ablation needle 35. Similarly, the outer contact 72 electrically couples to the outer conductor 16 of delivery needle 10. As used herein, “electrically coupled” shall indicate a coupling capable of conducting current at microwave frequencies. In this fashion, a microwave power source (not illustrated) coupled to the coaxial connector 75 will transmit energy through the coaxial transmission line 50 to the microwave antenna 40. First connector 70, and therefore coaxial connector 75, further comprises a nut 68 having internal threads 73 or other mechanical means for insuring firm connection between the coaxial connector 75 and a flexible coaxial cable coupled to the microwave power source. Nut 68 freely rotates about delivery needle 10.
In an alternative embodiment, first and second connectors 70 and 65, illustrated in
Regardless of whether the ablation needle 35 and the delivery needle couple together to create the coaxial transmission line 50, to minimize trauma and bleeding, particularly in organs like the liver that tend to bleed, the delivery needle 10 is preferably 17 gauge or higher. However, as illustrated in
Turning now to
The biopsy needle 30 may be of either an aspirating or coring type as is well known in the art. Note that the biopsy needle 30 may have a proximal handle 45. When the biopsy needle is inserted into the proximal port 15 of the delivery needle 10, the proximal handle 45 abuts against the proximal port 15, preventing further distal displacement within the lumen 20. The biopsy needle 30 may have a blunt distal end 31 or a sharpened distal end 32. In addition, the biopsy needle 30 may further comprise a stylet 29 having a matched point 34 to aid in strengthening or stiffening the biopsy needle 30 and assist piercing tissue with the needle 30. The biopsy needle 30 is preferably 20 to 23 gauge and most preferably 20 to 21 gauge. The lumen of the biopsy needle 30 is preferably greater than 0.017″ and most preferably at least 0.022″. The biopsy needle 30 may be inserted into the lumen 20 of delivery needle 10 and both inserted into tissue as a unit such that the biopsy needle 30 acts as an obturator 11. Use of either a biopsy needle 30 or the obturator 11 in this way allows the delivery needle 10 to have a flat distal end, lessening trauma to internal organs from movements of the delivery needle 10 during exchange of the biopsy needle 30 and the ablation needle 35.
Turning now to
Alternatively, the distal projection of the ablation needle 35 may form a dipole antenna 43 as illustrated in
In yet another embodiment, the distal projection of the ablation needle 35 may form a helical coiled antenna 51. The helical coiled antenna 51 comprises the center conductor 55 and surrounding dielectric material 60 as previously described. In addition, the center conductor 55 has an extension that forms coils 52 about the dielectric material 60. The coils 52 are electrically isolated from the delivery needle 10. Stauffer et al., (1995) Interstitial Heating Tech. In: Seegenschmiedt et al. (eds.), Thermoradiotherapy and Thermochemotherapy, vol. 1, Springer, pp. 279–320 provide additional discussion of suitable dipole 43 and helical coil antennas 51, the contents of which is hereby incorporated by reference.
Turning now to
As an alternative embodiment, instead of the coaxial connector 78, the delivery needle 10 may include a connector (not illustrated) comprising an outer portion of a coaxial connector and the ablation needle 35 may include a connector (not illustrated) comprising an inner portion of a coaxial connector. When the connectors are connected, the resulting coaxial connector is electrically coupled to the coaxial transmission line 61. In such an embodiment, the outer portion of the coaxial connector would have to electrically couple to the outer conductor 62 of the ablation needle 35.
It is to be noted that, regardless of the particular type of microwave antenna 40 implemented, the present invention provides advantages over prior art microwave antennas. In the present invention, the biopsy needle 30 and the delivery needle 10 may have already formed an insertion track before the microwave antenna 40 is inserted into an ablation site. Because the microwave antenna 40 may follow the existing insertion track, the microwave antenna 40 may possess a flat distal end. Prior art MCT microwave antennas typically had a sharpened distal end so that these antennas could be inserted into an ablation site. The SAR pattern of a microwave antenna 40 may be altered depending upon whether a flat or sharpened distal end is utilized. Thus, the present invention allows a clinician more control of the SAR patterns needed for a particular therapy.
Whether the ablation needle 35 and the delivery needle 10 are coupled to create the coaxial transmission line 50 or the ablation needle 35 includes the coaxial transmission line 61, the present invention will provide a variety of microwave antennas 40 which are inserted into a tumor through the lumen 20 of the delivery needle 10. The delivery needle 10 and the microwave antenna 40 together follow an insertion track in the body. The microwave antenna 40 may take a number of forms as previously described. Each of the forms, such as the monopole 41, has an effective antenna length which represents the longitudinal extent of tissue ablated by the microwave antenna 40 in the insertion track. The effective antenna length may depend upon the antenna design, the expected insertion depth, the expected amount of tissue perfusion, the expected duration and power of energy deliver, the frequency of the microwave power source, and additional factors. The effective antenna length may be greater, smaller or the same as the actual length of the physical components comprising the microwave antenna. Additionally, the field produced by the microwave antenna may be offset from the actual physical location of the antenna, either proximally or distally.
Track ablation is most efficiently performed only when the effective antenna length is accounted for during the procedure. Track ablation is necessary because tumors, such as liver tumors, can “seed” an insertion track as the microwave antenna 40 is withdrawn from the tumor. Therefore, it is beneficial to ablate the insertion track during withdrawal to kill any tumor cells displaced along the insertion track which would otherwise (potentially) act as “seeds” for future tumors. Moreover, track ablation helps to stem hemorrhage and bile leakage from the insertion track. After performing ablation of a tumor, the microwave antenna 40 may be withdrawn approximately an effective antenna length. Ablation would then be performed again, thus performing ablation in the insertion track without gaps and without excess overlap between successive ablations so as to kill displaced tumor cells while minimizing excess damage to the insertion track. Because only a small area surrounding the insertion track need be ablated, and to minimize damage to healthy tissue during track ablation, the clinician may decrease the diameter of the field of the antenna and/or lengthen the field to speed track ablation time. For example, a 48° C. isotherm may be desired 20 mm radially from the antenna during tumor ablation whereas the same 48° C. isotherm may be desired just 1 mm radially from the antenna during track ablation. These alterations to microwave field diameter and length may be made by decreasing the power or changing the frequency of the microwave power source. In addition or alternatively, the antenna field may be altered by changing the physical dimensions of the microwave antenna 40 by, for example, proximally or distally displacing the ablation needle 35 within the lumen 20 of the delivery needle 10. Alternatively, the ablation needle 35 used for tumor ablation could be withdrawn from the delivery needle 10 and replaced with an ablation needle 35 specialized for track ablation. This specialization would be such that the microwave antenna 40 would possess a field suitable for faster track ablation.
In a preferred embodiment of the present invention, a clinician may gauge whether the modular needle apparatus has been withdrawn a sufficient distance by observing a plurality of first markings 85 (illustrated in
A clinician would observe first markings 85 differently according to the type of procedure being performed. For example, in a percutaneous procedure, the clinician would observe first markings 85 as the delivery needle is withdrawn from the skin of a patient. In a laparoscopic procedure, because a trocar may have been used to access a target organ, the modular needle apparatus may have been introduced through a cannula so that the clinician views the first markings 85 as the delivery needle 10 is withdrawn from the cannula. In an open surgical or laparoscopic procedure, the clinician may view the first markings 85 as the delivery needle 10 is withdrawn from the liver.
The plurality of first markings may be visible to the human eye or may be imaged using alternative means. For example, the plurality of first markings 85 may comprise a diamagnetic or paramagnetic material that gives an artifact observable with MRI. As one of ordinary skill in the art will appreciate, the remainder of the modular needle apparatus may be made of MRI-compatible materials for use during an MRI imaged procedure. Alternatively, the plurality of first markings 85 may comprise a radiopaque material visible during a fluoroscopic procedure. Finally, the plurality of first markings 85 may comprise a material having, e.g., a roughened surface visible to ultrasound imaging systems. It is to be noted that if the markings are imaged by means other than direct vision (e.g., a fluoroscopic procedure), the plurality of first markings may be located on the ablation needle rather than being located on the delivery needle.
A second marking 86 (also illustrated in
Alternatively, if the procedure is performed using MRI, a second marking 86 comprised of, for example, diamagnetic or paramagnetic material that gives an artifact observable with MRI is desirable. If the procedure is performed using ultrasound, a second marking 86 that is visible on ultrasound is preferable. Finally, if the procedure is performed using fluoroscopy, a radiopaque second marking 86 is desirable. Regardless of the type of procedure performed, to use the second marking 86, the position of the outer surface of the liver would need to be known by using the imaging systems used to observe the second marking 86 or by another imaging system either simultaneously or in sequence. Similarly to the plurality of first markings, the second marking 86 may be located on the ablation needle rather than on the delivery needle if the second marking is observed through an imaging system other than direct vision with the human eye.
It is to be noted that for the embodiments of the modular needle apparatus illustrated in
To assist coupling a microwave power source to the microwave antenna 40, the coaxial connector 75, 76 and 78 as used in the various embodiments described herein may comprise a standard coaxial connector such as an SMA connector. Alternatively, the coaxial connector may be a coaxial connector of a custom design for ease of assembly.
The present invention also includes a system for biopsy and ablation of tumors. The system comprises a modular needle apparatus in one of the various embodiments as described herein. An example system is illustrated in
The present invention includes methods of biopsy and ablation using the disclosed modular needle apparatus. Turning now to
As an alternative to the steps shown in
After drawing a tissue sample into biopsy needle 30, the biopsy needle 30 is withdrawn from the lumen 20 of the delivery needle 10 as illustrated in
In embodiments of the invention wherein the maximum allowable withdrawal is gauged by observing the second marking 86 and stopping a withdrawal step when the second marking 86 is adjacent the surface of the liver 90 (indicating the proximal edge of the antenna pattern of the microwave antenna 40 is near the surface of the liver 90), the length over which the final ablation is performed may overlap the previously ablated track more so than the previous ablations. As described previously, the clinician will observe the second marking 86 differently depending upon the type of procedure being performed. If the procedure is an open surgical or laparoscopic one in which the surface of the liver 90 is directly visible, the clinician may view the second marking 86 directly. If the procedure is performed using MRI, the clinician may view the second marking 86 using MRI (provided that marking 86 is visible to MRI). Alternatively, if the procedure is performed using ultrasound or fluoroscopy, the second marking 86 will be viewed accordingly.
It is to be noted that, although the method of track ablation just described uses the modular needle apparatus of the present invention, the present invention contemplates a method of track ablation using prior art microwave ablation devices which include the plurality of first markings 85 and the second marking 86. Furthermore, the plurality of first markings 85 and second marking 86 and the method of using the same for track ablation may be applied to other interstitial thermotherapy procedures such as RF ablation, cryoablation or DC procedures. For example, on a cryoprobe, the plurality of first markings would be spaced apart the equivalent of the “effective antenna length” for the cryoprobe. This distance would correspond to the effective extent of ablated tissue produced by the cryoprobe during an ablation procedure.
Many widely differing embodiments of the present invention may be constructed without departing from the spirit and scope of the present invention. Therefore, it should be understood that the present invention is not to be limited to the particular forms or methods disclosed, but to the contrary, the present invention is to cover all modifications, equivalents and alternatives falling within the spirit and scope of the appended claims.
This application is a continuation of U.S. patent application Ser. No. 09/827,528, filed Apr. 6, 2001, now U.S. Pat. No. 6,582,426 which is a continuation of U.S. patent application Ser. No. 09/356,077, filed Jul. 16, 1999, now U.S. Pat. No. 6,355,033 which is a continuation-in-part of U.S. patent application Ser. No. 09/336,371, filed Jun. 17, 1999, now U.S. Pat. No. 6,306,132 each of which is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
2022065 | Wappler | Nov 1935 | A |
2047535 | Wappler | Jul 1936 | A |
3330278 | Santomieri | Jul 1967 | A |
3351463 | Rozner et al. | Nov 1967 | A |
3516412 | Ackerman | Jun 1970 | A |
3598108 | Jamshidi et al. | Aug 1971 | A |
3714851 | Orser | Feb 1973 | A |
3753700 | Harrison et al. | Aug 1973 | A |
3886944 | Jamshidi | Jun 1975 | A |
3890977 | Wilson | Jun 1975 | A |
4010756 | DuMont et al. | Mar 1977 | A |
4103690 | Harris | Aug 1978 | A |
4274408 | Nimrod | Jun 1981 | A |
4311154 | Sterzer et al. | Jan 1982 | A |
4341226 | Peters | Jul 1982 | A |
4402328 | Doring | Sep 1983 | A |
4448198 | Turner | May 1984 | A |
4557272 | Carr | Dec 1985 | A |
4565200 | Cosman | Jan 1986 | A |
4592356 | Gutierrez | Jun 1986 | A |
4595007 | Mericle | Jun 1986 | A |
4612940 | Kasevich et al. | Sep 1986 | A |
4616656 | Nicholson et al. | Oct 1986 | A |
4621642 | Chen | Nov 1986 | A |
4633880 | Osypka et al. | Jan 1987 | A |
4658836 | Turner | Apr 1987 | A |
4665906 | Jervis | May 1987 | A |
4682606 | DeCaprio | Jul 1987 | A |
4700716 | Kasevich et al. | Oct 1987 | A |
4776086 | Kasevich et al. | Oct 1988 | A |
4799495 | Hawkins et al. | Jan 1989 | A |
4800899 | Elliott | Jan 1989 | A |
4825880 | Stauffer et al. | May 1989 | A |
4869259 | Elkins | Sep 1989 | A |
4925445 | Sakamoto et al. | May 1990 | A |
4966583 | Debbas | Oct 1990 | A |
5011473 | Gatturna | Apr 1991 | A |
5018530 | Rank et al. | May 1991 | A |
5059197 | Urie et al. | Oct 1991 | A |
5067957 | Jervis | Nov 1991 | A |
5085659 | Rydell | Feb 1992 | A |
5122136 | Guglielmi et al. | Jun 1992 | A |
5158084 | Ghiatas | Oct 1992 | A |
5171255 | Rydell | Dec 1992 | A |
5183463 | Debbas | Feb 1993 | A |
5190054 | Fetter et al. | Mar 1993 | A |
5190546 | Jervis | Mar 1993 | A |
5197482 | Rank et al. | Mar 1993 | A |
5205829 | Lituchy | Apr 1993 | A |
5217027 | Hermens | Jun 1993 | A |
5221269 | Miller et al. | Jun 1993 | A |
5246438 | Langberg | Sep 1993 | A |
5249585 | Turner et al. | Oct 1993 | A |
5282845 | Bush et al. | Feb 1994 | A |
5300068 | Rosar et al. | Apr 1994 | A |
5301682 | Debbas | Apr 1994 | A |
5314466 | Stern et al. | May 1994 | A |
5344441 | Gronauer | Sep 1994 | A |
5350419 | Bendel et al. | Sep 1994 | A |
5353804 | Kornberg et al. | Oct 1994 | A |
5370644 | Langberg | Dec 1994 | A |
5370675 | Edwards et al. | Dec 1994 | A |
5405346 | Grundy et al. | Apr 1995 | A |
5409004 | Sloan | Apr 1995 | A |
5462062 | Rubinstein et al. | Oct 1995 | A |
5470308 | Edwards et al. | Nov 1995 | A |
5472441 | Edwards et al. | Dec 1995 | A |
5486183 | Middleman et al. | Jan 1996 | A |
5488958 | Topel et al. | Feb 1996 | A |
5500012 | Brucker et al. | Mar 1996 | A |
5507743 | Edwards et al. | Apr 1996 | A |
5520684 | Imran | May 1996 | A |
5536240 | Edwards et al. | Jul 1996 | A |
5536267 | Edwards et al. | Jul 1996 | A |
5540683 | Ichikawa et al. | Jul 1996 | A |
5556377 | Rosen et al. | Sep 1996 | A |
5556410 | Mittermeir et al. | Sep 1996 | A |
5558673 | Edwards et al. | Sep 1996 | A |
5578030 | Levin | Nov 1996 | A |
5599294 | Edwards et al. | Feb 1997 | A |
5599295 | Rosen et al. | Feb 1997 | A |
5599346 | Edwards et al. | Feb 1997 | A |
5607389 | Edwards et al. | Mar 1997 | A |
5672173 | Gough et al. | Sep 1997 | A |
5672174 | Gough et al. | Sep 1997 | A |
5683384 | Gough et al. | Nov 1997 | A |
5685853 | Bonnet | Nov 1997 | A |
5700243 | Narciso, Jr. | Dec 1997 | A |
5709697 | Ratcliff et al. | Jan 1998 | A |
5720718 | Rosen et al. | Feb 1998 | A |
5735847 | Gough et al. | Apr 1998 | A |
5741225 | Lax et al. | Apr 1998 | A |
5749887 | Heske et al. | May 1998 | A |
5776176 | Rudie | Jul 1998 | A |
5794626 | Kieturakis | Aug 1998 | A |
5795308 | Russin | Aug 1998 | A |
5800484 | Gough et al. | Sep 1998 | A |
5800486 | Thome et al. | Sep 1998 | A |
5807339 | Bostrom et al. | Sep 1998 | A |
5810804 | Gough et al. | Sep 1998 | A |
5853366 | Dowlatshahi | Dec 1998 | A |
5855576 | LeVeen et al. | Jan 1999 | A |
5861002 | Desai | Jan 1999 | A |
5863290 | Gough et al. | Jan 1999 | A |
5871523 | Fleischman et al. | Feb 1999 | A |
5879357 | Heaton et al. | Mar 1999 | A |
5882316 | Chu et al. | Mar 1999 | A |
5897554 | Chia et al. | Apr 1999 | A |
5902310 | Foerster et al. | May 1999 | A |
5904690 | Middleman et al. | May 1999 | A |
5904691 | Barnett et al. | May 1999 | A |
5904709 | Arndt et al. | May 1999 | A |
5938692 | Rudie | Aug 1999 | A |
5941890 | Voegele et al. | Aug 1999 | A |
5954655 | Hussman | Sep 1999 | A |
5954719 | Chen et al. | Sep 1999 | A |
5957969 | Warner et al. | Sep 1999 | A |
5974343 | Brevard et al. | Oct 1999 | A |
5980563 | Tu et al. | Nov 1999 | A |
5989265 | Bouquet De La Joliniere et al. | Nov 1999 | A |
6007495 | Matula | Dec 1999 | A |
6016811 | Knopp et al. | Jan 2000 | A |
6019757 | Scheldrup | Feb 2000 | A |
6022362 | Lee et al. | Feb 2000 | A |
6026331 | Feldberg et al. | Feb 2000 | A |
6027501 | Goble et al. | Feb 2000 | A |
6027524 | Petit | Feb 2000 | A |
6032078 | Rudie | Feb 2000 | A |
6039735 | Greep | Mar 2000 | A |
6050954 | Mittermeier | Apr 2000 | A |
6051008 | Saadat et al. | Apr 2000 | A |
6053876 | Fisher | Apr 2000 | A |
6053925 | Barnhart | Apr 2000 | A |
6056744 | Edwards | May 2000 | A |
6059780 | Gough et al. | May 2000 | A |
6073051 | Sharkey et al. | Jun 2000 | A |
6080113 | Heneveld et al. | Jun 2000 | A |
6080114 | Russin | Jun 2000 | A |
6080150 | Gough | Jun 2000 | A |
6097985 | Kasevich et al. | Aug 2000 | A |
6106518 | Wittenberger et al. | Aug 2000 | A |
6106524 | Eggers et al. | Aug 2000 | A |
6122551 | Rudie et al. | Sep 2000 | A |
6134476 | Arndt et al. | Oct 2000 | A |
6146378 | Mikus et al. | Nov 2000 | A |
6146379 | Fleischman et al. | Nov 2000 | A |
6146657 | Unger | Nov 2000 | A |
6162216 | Guziak et al. | Dec 2000 | A |
6162261 | Kempter et al. | Dec 2000 | A |
6176856 | Jandak et al. | Jan 2001 | B1 |
6178354 | Gibson | Jan 2001 | B1 |
6181970 | Kasevich | Jan 2001 | B1 |
6217528 | Koblish et al. | Apr 2001 | B1 |
6223086 | Carl et al. | Apr 2001 | B1 |
6233490 | Kasevich | May 2001 | B1 |
6245064 | Lesh et al. | Jun 2001 | B1 |
6245318 | Klibanov et al. | Jun 2001 | B1 |
6251128 | Knopp et al. | Jun 2001 | B1 |
6275738 | Kasevich et al. | Aug 2001 | B1 |
6277113 | Berube | Aug 2001 | B1 |
6290715 | Sharkey et al. | Sep 2001 | B1 |
6306132 | Moorman et al. | Oct 2001 | B1 |
6308091 | Avitall | Oct 2001 | B1 |
6325796 | Berube et al. | Dec 2001 | B1 |
6330479 | Stauffer | Dec 2001 | B1 |
6346104 | Daly et al. | Feb 2002 | B1 |
6347251 | Deng | Feb 2002 | B1 |
6355033 | Moorman et al. | Mar 2002 | B1 |
6405733 | Fogarty et al. | Jun 2002 | B1 |
6419653 | Edwards et al. | Jul 2002 | B1 |
6471696 | Berube et al. | Oct 2002 | B1 |
6469738 | Carr | Dec 2002 | B1 |
6514251 | Ni et al. | Feb 2003 | B1 |
6530922 | Cosman et al. | Mar 2003 | B1 |
6564806 | Fogarty et al. | May 2003 | B1 |
6569159 | Edwards et al. | May 2003 | B1 |
6582426 | Moorman et al. | Jun 2003 | B1 |
6652520 | Moorman et al. | Nov 2003 | B1 |
6663624 | Edwards et al. | Dec 2003 | B1 |
6685700 | Behl et al. | Feb 2004 | B1 |
6699241 | Rappaport et al. | Mar 2004 | B1 |
6722371 | Bush et al. | Apr 2004 | B1 |
6752154 | Fogarty et al. | Jun 2004 | B1 |
6752767 | Turovskiy et al. | Jun 2004 | B1 |
6878147 | Prakash et al. | Apr 2005 | B1 |
20010001819 | Lee at al. | May 2001 | A1 |
20010037812 | Dobak, III et al. | Nov 2001 | A1 |
20010051131 | Unger | Dec 2001 | A1 |
20020022832 | Mikus et al. | Feb 2002 | A1 |
20020058932 | Moorman et al. | May 2002 | A1 |
20020059938 | Fogarty et al. | May 2002 | A1 |
20020087151 | Mody et al. | Jul 2002 | A1 |
20020133148 | Daniel et al. | Sep 2002 | A1 |
20020147444 | Shah et al. | Oct 2002 | A1 |
20020198520 | Coen et al. | Dec 2002 | A1 |
20030004506 | Messing | Jan 2003 | A1 |
20030065317 | Rudie et al. | Apr 2003 | A1 |
20030069578 | Hall et al. | Apr 2003 | A1 |
20030088242 | Prakash et al. | May 2003 | A1 |
20030109862 | Prakash et al. | Jun 2003 | A1 |
20030195499 | Prakash et al. | Oct 2003 | A1 |
20030195500 | Moorman et al. | Oct 2003 | A1 |
20030208199 | Keane | Nov 2003 | A1 |
20040168692 | Fogarty et al. | Sep 2004 | A1 |
20040267156 | Turovskiy et al. | Dec 2004 | A1 |
20050062666 | Prakash et al. | Mar 2005 | A1 |
20050085881 | Prakash et al. | Apr 2005 | A1 |
Number | Date | Country |
---|---|---|
0 385 604 | Sep 1990 | EP |
0 395 997 | Nov 1990 | EP |
0 481 685 | Apr 1992 | EP |
0 667 126 | Aug 1995 | EP |
0 829 232 | Mar 1998 | EP |
0 908 154 | Apr 1999 | EP |
0 908 156 | Apr 1999 | EP |
WO 8806864 | Sep 1988 | WO |
WO 9212678 | Aug 1992 | WO |
WO 9320767 | Oct 1993 | WO |
WO 9320768 | Oct 1993 | WO |
WO 9627328 | Sep 1996 | WO |
WO 9634571 | Nov 1996 | WO |
WO 9748449 | Dec 1997 | WO |
WO 9748450 | Dec 1997 | WO |
WO 9748451 | Dec 1997 | WO |
WO 9806341 | Feb 1998 | WO |
WO 9904704 | Feb 1999 | WO |
WO 9925248 | May 1999 | WO |
WO 9943268 | Sep 1999 | WO |
WO 9944506 | Sep 1999 | WO |
WO 9956642 | Nov 1999 | WO |
WO 9956643 | Nov 1999 | WO |
WO 9956812 | Nov 1999 | WO |
WO 9958065 | Nov 1999 | WO |
WO 9966834 | Dec 1999 | WO |
WO 0010471 | Mar 2000 | WO |
WO 0012009 | Mar 2000 | WO |
WO 0012010 | Mar 2000 | WO |
WO 0013602 | Mar 2000 | WO |
WO 0016697 | Mar 2000 | WO |
WO 0024320 | May 2000 | WO |
WO 0028913 | May 2000 | WO |
WO 0030531 | Jun 2000 | WO |
WO 0033743 | Jun 2000 | WO |
WO 0049957 | Aug 2000 | WO |
WO 0056239 | Sep 2000 | WO |
WO 0057811 | Oct 2000 | WO |
WO 0100114 | Jan 2001 | WO |
WO 0105317 | Jan 2001 | WO |
WO 0105320 | Jan 2001 | WO |
WO 0160235 | Aug 2001 | WO |
WO 03034932 | May 2003 | WO |
WO 03039385 | May 2003 | WO |
WO 03088806 | Oct 2003 | WO |
WO 03088858 | Oct 2003 | WO |
WO 05011049 | Feb 2005 | WO |
Number | Date | Country | |
---|---|---|---|
20030195500 A1 | Oct 2003 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09827528 | Apr 2001 | US |
Child | 10428362 | US | |
Parent | 09356077 | Jul 1999 | US |
Child | 09827528 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09336371 | Jun 1999 | US |
Child | 09356077 | US |